Influenza

With the FDA approval, Abbot now anticipates to offer new assays for use this fall.

The single-dose, oral therapy becomes the first new influenza antiviral with a novel mechanism of action approved by the FDA in nearly 20 years.

Research indicates that influenza vaccine effectiveness was low but effective in preventing influenza-related hospitalization during the 2016-2017 flu season in Canada.

Investigators find school-located influenza vaccination increased coverage and decreased school absence and influenza hospitalization.

New research suggests that flu vaccination setting is associated with vaccination timing.

High-risk individuals, such as those with cardiopulmonary and other chronic conditions, are protected from flu-related hospitalizations with the vaccine.

Roche's investigative drug could become the first single-dose oral antiviral approved for the US market in December.

Unvaccinated individuals can also benefit from the flu vaccine.

Updates in trivalent vaccines and vaccination clearance for egg-allergic patients were among the updated recommendations for pediatric influenza prevention and treatment this upcoming 2018-2019 flu season.

Less than one-third received both influnza and Tdap vaccination during their pregnancies, citing limited understanding or assurance of their benefits and safety.

Investigators will assess the efficacy, safety, and tolerability of NanoFlu doses and formulations—both adjuvanted and unadjuvanted—in comparison to a pair of US marketed vaccines.

Investigators found that active choice intervention correlated with a nearly 10% increased likelihood of patients receiving the seasonal flu vaccine.

With another randomized, controlled trial involving patients at high risk for flu complications currently underway, investigators found that baloxavir may provide an option for patients with uncomplicated influenza.

New recommendations from the CDC's Advisory Committee on Immunization Practices reveal that health care providers have the intranasally-administered live attenuated influenza vaccine (LAIV) among their arsenal of available vaccines for the 2018-2019 flu season.

Troy Trygstad spoke with MD Magazine ® about the potential for a pandemic flu and emphasized that there’s no “crystal ball” to help predict this.

These mistakes can be as simple as a worker touching their face before removing contaminated gloves.

Troy Trygstad spoke with MD Magazine® about the upcoming flu season and emphasized how different clinicians and parts of the healthcare system can play a role in promoting immunization.

After a high-volume flu season driven by outbreak of the mutated H3N2 strain, Sanofi has bolstered its vaccine class with options specific to older populations.

A study of pediatric patients with asthma admitted to emergency departments has determined that while rhinovirus is the most prevalent infection, it is the non-rhinovirus pathogens that are associated with an increased absolute risk of treatment failure.

The antiviral treatment for patients at high risk of complications from influenza met the primary objective of efficacy measured by time to improvement of symptoms compared to placebo.

If approved, this would be the first oral, 1-dose antiviral and the first medicine with a novel proposed mechanism of action to treat the flu in about 20 years.

Between 60-80% of pediatric asthma exacerbations are triggered by respiratory pathogens. For most children, the common cold is the culprit.

If approved, the same 0.5 mL dose vaccination can be used with all patients ages 6 months and older for whom flu vaccination is recommended.

“Original antigenic sin" is the result of slight year-to-year virus change that are not caught by antibodies produced by the body during previous vaccinations.

Representatives from NIAID and St. Jude Children's Research Hospital dispel exaggerations on the current flu outbreak.

The influenza vaccine can now be used to protect recommended persons aged 6 months and older.

According to 28 studies, there is no greater risk of reaction posed for those without an allergy.

It's normal to find misleading videos online, but scientists have found that even the ones published by health systems aren't up to snuff.

The CAPSTONE-1 trial demonstrated a new antiviral aimed to reduce flu symptoms with possible NDA submission.

The CDC-based study sought to combat influenza epidemic risks with an earlier jump on outbreak detection.